Journal of Vaccine Research 2024, Vol.14, No.6, 316-323 http://medscipublisher.com/index.php/jvr 319 and have no recurrence or serious side effects of the disease. These findings support the use of mRNA vaccines in susceptible populations, but additional doses or combined vaccination strategies may be required to improve efficacy. 5 Technical Challenges in mRNA Vaccine Development 5.1 Stability issues of mRNA mRNA vaccine stability is a concern due to the nature of mRNA and its relationship with lipid nanoparticles (LNPs). mRNA is prone to degradation, and environmental factors such as temperature and pH can further exacerbate the degradation problem. mRNA instability can affect vaccine efficacy and worldwide availability (Shou and Cai, 2024). The key parameters for controlling mRNA stability include mRNA structure, ancillary materials, LNP delivery vehicles and manufacturing processes. Optimization can significantly improve the stability of mRNA vaccines through these parameters (Cromelin et al., 2020). Additionally, rational design of mRNA preparations and the use of advanced analytical technologies for monitoring stability are also of paramount significance for maximizing the stability of mRNA vaccines (Am, 2023). 5.2 Cold chain storage and transportation requirements mRNA vaccines would also have to be stored and shipped under strict cold chain conditions to maintain their stability and efficacy. Pfizer-BioNTech and Moderna COVID-19 vaccines, for example, have to be stored at ultra-low temperature conditions, which poses a huge logistical challenge for resource-limited countries that lack the infrastructure to offer the same. To address these issues and enable global delivery of vaccines, it is critical to improve the stability of mRNA vaccines at elevated temperatures. Techniques such as freeze-drying and capillary-mediated vitrification (CMV) offer potential for improved thermal stability of mRNA vaccines that could restrict ultra-low-temperature storage (Uddin and Roni, 2021). 5.3 Production costs and technical barriers mRNA vaccine manufacturing entails complex and costly processes like mRNA synthesis, lipid nanoparticle encapsulation, and multi-step purification. These demand advanced technologies and facilities, which are barriers to mass production and global promotion. The production costs are high to some extent because of the need for highly pure raw materials and multi-step manufacturing processes in order to maintain the stability and effectiveness of the final product (Rosa et al., 2021). The focus is now on optimizing manufacturing processes, reducing costs, and overcoming technical hurdles. Technological innovation within the manufacturing process and process optimization are critical in improving the affordability and accessibility of mRNA vaccines (Kis, 2022). 6 Advances in Cutting-Edge Technologies for mRNA Vaccines 6.1 Optimization of delivery systems through nanotechnology Nanotechnology has played a key role in the creation of mRNA vaccine delivery platforms. Lipid nanoparticles (LNPs) have been revolutionary, not just delivering mRNA to target cells effectively but also as adjuvants to provoke the immune system. LNPs stabilize mRNA against ribonucleases and keep it stable and bioavailable in vivo. Additionally, nanoparticles have been engineered to improve mRNA vaccines' physicochemical properties, which result in their greater cellular uptake and endosomal release (Kim et al., 2021)(Figure 2). All this has contributed enormously to the achievement of mRNA vaccine success, such as that of SARS-CoV-2 (Rzymski et al., 2023). 6.2 Contributions of Synthetic Biology to mRNA Modifications Synthetic biology has helped to advance mRNA vaccines by enhancing the stability, translation efficiency, and immunogenicity of it. RNA chemistry advancements have made it possible to incorporate modified nucleosides, which not only reduces the intrinsic immune response but also enhances the half-life of mRNA molecules (Ismail et al., 2020). In addition, synthetic biology technologies have made it possible to design mRNA sequences to allow efficient expression of proteins, thereby making the overall effectiveness of the vaccine better (Pardi et al., 2020). Such adjustments are significant in the development of safe and effective mRNA vaccines and can be used extensively to prevent and control infectious diseases and cancer immunotherapy.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==